At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health
crisis causing major challenges for clinical care in patients with gastrointestinal diseases …

Background The global COVID-19 pandemic has impacted on the mental health of
individuals, particularly those with chronic illnesses. We aimed to quantify stress, anxiety …

Background Patients with inflammatory bowel disease (IBD) on immune-modifying treatment
could be at an increased risk for severe coronavirus disease 2019 (COVID-19); thus, data on …

Background There are concerns that individuals with chronic immune‐mediated diseases
are at increased risk of COVID‐19 and related severe adverse outcome, including intensive …

Abstract Coronavirus disease-19 (COVID-19), caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), represents one of the biggest challenges of 21st …

The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

CT-P13 is the first subcutaneous infliximab molecule approved for the management of
inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a …

Background Vaccination against COVID-19 is a major public health challenge, including the
community of patients with inflammatory bowel disease. Vaccination coverage is suboptimal …